Compare Aventis Pharma with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs GSK PHARMA - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA GSK PHARMA SANOFI INDIA/
GSK PHARMA
 
P/E (TTM) x 40.4 32.3 124.8% View Chart
P/BV x 7.1 12.9 54.9% View Chart
Dividend Yield % 1.2 1.2 100.3%  

Financials

 SANOFI INDIA   GSK PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
GSK PHARMA
Mar-19
SANOFI INDIA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs6,8403,595 190.3%   
Low Rs4,6301,253 369.5%   
Sales per share (Unadj.) Rs1,203.1184.7 651.5%  
Earnings per share (Unadj.) Rs165.326.3 628.5%  
Cash flow per share (Unadj.) Rs209.929.2 719.6%  
Dividends per share (Unadj.) Rs84.0020.00 420.0%  
Dividend yield (eoy) %1.50.8 177.5%  
Book value per share (Unadj.) Rs963.6126.3 762.8%  
Shares outstanding (eoy) m23.03169.40 13.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.813.1 36.3%   
Avg P/E ratio x34.792.2 37.6%  
P/CF ratio (eoy) x27.383.1 32.9%  
Price / Book Value ratio x6.019.2 31.0%  
Dividend payout %50.876.1 66.8%   
Avg Mkt Cap Rs m132,078410,626 32.2%   
No. of employees `0003.35.0 66.6%   
Total wages/salary Rs m4,0685,372 75.7%   
Avg. sales/employee Rs Th8,393.86,306.7 133.1%   
Avg. wages/employee Rs Th1,232.41,083.1 113.8%   
Avg. net profit/employee Rs Th1,153.0898.0 128.4%   
INCOME DATA
Net Sales Rs m27,70831,281 88.6%  
Other income Rs m8971,023 87.7%   
Total revenues Rs m28,60532,304 88.5%   
Gross profit Rs m6,2356,009 103.8%  
Depreciation Rs m1,027486 211.3%   
Interest Rs m76 116.7%   
Profit before tax Rs m6,0986,540 93.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m2,2922,373 96.6%   
Profit after tax Rs m3,8064,454 85.5%  
Gross profit margin %22.519.2 117.1%  
Effective tax rate %37.636.3 103.6%   
Net profit margin %13.714.2 96.5%  
BALANCE SHEET DATA
Current assets Rs m15,92220,061 79.4%   
Current liabilities Rs m6,23514,543 42.9%   
Net working cap to sales %35.017.6 198.2%  
Current ratio x2.61.4 185.1%  
Inventory Days Days6457 112.1%  
Debtors Days Days2114 148.4%  
Net fixed assets Rs m7,53914,343 52.6%   
Share capital Rs m2301,694 13.6%   
"Free" reserves Rs m21,96219,704 111.5%   
Net worth Rs m22,19221,398 103.7%   
Long term debt Rs m02 0.0%   
Total assets Rs m29,83939,113 76.3%  
Interest coverage x872.11,091.0 79.9%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.90.8 116.1%   
Return on assets %12.811.4 112.1%  
Return on equity %17.220.8 82.4%  
Return on capital %27.531.9 86.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,587534 1,420.8%   
Fx outflow Rs m7,1457,091 100.8%   
Net fx Rs m442-6,557 -6.7%   
CASH FLOW
From Operations Rs m3,7393,994 93.6%  
From Investments Rs m-731-1,433 51.0%  
From Financial Activity Rs m-1,972-3,584 55.0%  
Net Cashflow Rs m1,036-1,023 -101.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 60.4 50.7 119.1%  
Indian inst/Mut Fund % 14.4 10.2 141.2%  
FIIs % 14.6 23.8 61.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 15.4 68.2%  
Shareholders   15,184 102,036 14.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   ORCHID PHARMA LTD  WYETH LTD  ASTRAZENECA PHARMA  SUVEN LIFESCIENCES  CIPLA  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 72 Points Lower; Capital Goods and Auto Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day marginally lower.

Related Views on News

SANOFI INDIA Surges by 5%; BSE HEALTHCARE Index Up 1.4% (Market Updates)

Nov 18, 2019 | Updated on Nov 18, 2019

SANOFI INDIA share price has surged by 5% and its current market price is Rs 6,820. The BSE HEALTHCARE is up by 1.4%. The top gainers in the BSE HEALTHCARE Index are SANOFI INDIA (up 5.0%) and GLENMARK PHARMA (up 20.6%). The top losers are FORTIS HEALTHCARE (down 0.1%) and CIPLA (down 0.3%).

ABBOTT INDIA at All Time High; BSE HEALTHCARE Index Up 1.0% (Market Updates)

Nov 18, 2019 | Updated on Nov 18, 2019

ABBOTT INDIA share price has hit an all time high at Rs 13,200 (up 5.4%). The BSE HEALTHCARE Index is up by 1.0%. Among the top gainers in the BSE HEALTHCARE Index today are ABBOTT INDIA (up 5.4%) and SANOFI INDIA (up 3.5%). The top losers include LAURUS LABS LTD and BLISS GVS PHARMA .

ABBOTT INDIA at All Time High; BSE HEALTHCARE Index Up 0.7% (Market Updates)

Nov 18, 2019 | Updated on Nov 18, 2019

ABBOTT INDIA share price has hit an all time high at Rs 12,550 (up 0.8%). The BSE HEALTHCARE Index is up by 0.7%. Among the top gainers in the BSE HEALTHCARE Index today are ABBOTT INDIA (up 0.8%) and SANOFI INDIA (up 0.7%). The top losers include BLISS GVS PHARMA and CAPLIN POINT .

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Nov 18, 2019 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS